Effective Trial Design: Clinical Trials in Small Patient Populations

To mark the occasion of Rare Disease Day 2021, we will be repeating our complimentary webinar “Effective Trial Design: Clinical Trials in Small Patient Populations”. The second edition will take place on the 4th of March – make sure you book your seat!

During this webinar, we will present several design options for clinical trials in indications with small populations. These include:

  • Designs where each patient serves as his/her own control
  • Designs where the control group is based on historical data
  • Designs that allow changes in the protocol of an ongoing trial

We will discuss the benefits of these designs and how they can solve the challenges inherent in these types of trials: determining a meaningful difference in clinical outcomes that can be detected between treatment groups and extended time to recruit the necessary number of patients.

What will you learn?

  • Available options for study design in indications with small patient populations
  • Advantages and disadvantages of each design
  • How to decide on appropriate design for planned clinical trials

Register to attend the complimentary webinar “Effective Trial Design: Clinical Trials in Small Patient Populations” now 

The webinar was conducted by Thomas Zwingers, Statistical Consultant of CROS NT.

Thomas has been working in the clinical trial environment since 1980. He is specialized in statistical analysis and reporting with particular expertise in Adaptive Trial Design. Prior to joining CROS NT, Thomas ran his own biometrics consulting CRO in Germany for over 20 years. During this time, he gained a considerable amount of experience in Dermatology, Respiratory and Oncology studies.
Thomas holds a Master’s degree in Cybernetics from the Technical University of Munich. He is a member of numerous international associations, including the Biometric Society, International Society for Clinical Biostatistics, and the Society for Clinical Trials. He has written and collaborated on over 100 publications in pharmaceutical and clinical trial statistics.